3136046420220409
2050-0068872019Clinical & translational immunologyClin Transl ImmunologyAssociations of pathogen-specific and host-specific characteristics with disease outcome in patients with Staphylococcus aureus bacteremic pneumonia.e01070e01070e0107010.1002/cti2.1070To understand the relationships of Staphylococcus aureus (SA) bacteremic pneumonia (SABP) outcome with patient-specific and SA-specific variables.We analysed SA bloodstream isolates and matching sera in SABP patients by sequencing SA isolates (n = 50) and measuring in vitro AT production, haemolytic activity and expression of ClfA and ClfB. Controls were sera from gram-negative bacteremia patients with or without pneumonia and uninfected subjects. Levels of IgGs, IgMs and neutralizing antibodies (NAbs) against SA antigens were quantified and analysed by one-way ANOVA. Associations of patient outcomes with patient variables, antibody levels and isolate characteristics were evaluated by univariate and multivariate logistic regression analyses.SABP patients had higher levels of IgGs against eight virulence factors and anti-alpha toxin (AT) NAbs than uninfected controls. Levels of IgG against AT and IgMs against ClfA, FnbpA and SdrC were higher in clinically cured SABP patients than in clinical failures. Anti-LukAB NAb levels were elevated in all cohorts. Increased odds of cure correlated with higher haemolytic activity of SA strains, longer time between surgery and bacteremia (> 30 days), longer duration of antibiotic therapy, lower acute physiology and total APACHE II scores, lack of persistent fever for > 72 h and higher levels of antibodies against AT (IgG), ClfA (IgM), FnbpA (IgM) and SdrC (IgM).Limitations included the cross-sectional observational nature of the study, small sample size and inability to measure antibody levels against all SA virulence factors.Our results suggest that SABP patients may benefit from immunotherapy targeting multiple SA antigens.Sharma-KuinkelBatu KBKDivision of Infectious Diseases, Department of Medicine, Duke University Durham NC USA.TkaczykChristineCMicrobial Sciences, AstraZeneca Gaithersburg MD USA.BonnellJessicaJMicrobial Sciences, AstraZeneca Gaithersburg MD USA.YuLiLStatistical Sciences, AstraZeneca Gaithersburg MD USA.TovchigrechkoAndreyAData Science & Artificial Intelligence, AstraZeneca Gaithersburg MD USA.TaborDavid EDEMicrobial Sciences, AstraZeneca Gaithersburg MD USA.ParkLawrence PLPDivision of Infectious Diseases, Department of Medicine, Duke University Durham NC USA.RuffinFeliciaFDivision of Infectious Diseases, Department of Medicine, Duke University Durham NC USA.EsserMark TMTMicrobial Sciences, AstraZeneca Gaithersburg MD USA.SellmanBret RBRMicrobial Sciences, AstraZeneca Gaithersburg MD USA.FowlerVance GVGJrDivision of Infectious Diseases, Department of Medicine, Duke University Durham NC USA.RuzinAlexeyAMicrobial Sciences, AstraZeneca Gaithersburg MD USA.engJournal Article20190719
AustraliaClin Transl Immunology1016382682050-0068Staphylococcus aureusantibody responsebacteremiapatient outcomepneumoniavirulence201936201962420196302019731602019731602019731612019719epublish31360464PMC664000210.1002/cti2.1070CTI21070 David MZ, Daum RS. Community‐associated methicillin‐resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010; 23: 616–687.PMC290166120610826 Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin‐resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis 2007; 13: 1840–1846.PMC287676118258033 Klevens RM, Morrison MA, Nadle J et al Invasive methicillin‐resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298: 1763–1771.17940231 Kuehnert MJ, Hill HA, Kupronis BA et al Methicillin‐resistant Staphylococcus aureus hospitalizations, United States. Emerg Infect Dis 2005; 11: 868–872.PMC336760915963281 De la Calle C, Morata L, Cobos‐Trigueros N et al Staphylococcus aureus bacteremic pneumonia. Eur J Clin Microbiol Infect Dis 2016; 35: 497–502.26780692 Boucher HW, Talbot GH, Bradley JS et al Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1–12.19035777 Fowler VG Jr, Boucher HW, Corey GR et al Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus . N Engl J Med 2006; 355: 653–665.16914701 Sanchez Garcia M, de la Torre MA, Morales G et al Clinical outbreak of linezolid‐resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303: 2260–2264.20530779 Thammavongsa V, Kim HK, Missiakas D et al Staphylococcal manipulation of host immune responses. Nat Rev Microbiol 2015; 13: 529–543.PMC462579226272408 Jacobsson G, Colque‐Navarro P, Gustafsson E et al Antibody responses in patients with invasive Staphylococcus aureus infections. Eur J Clin Microbiol Infect Dis 2010; 29: 715–725.20383551 Adhikari RP, Ajao AO, Aman MJ et al Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis 2012; 206: 915–923.22807524 Fritz SA, Tiemann KM, Hogan PG et al A serologic correlate of protective immunity against community‐onset Staphylococcus aureus infection. Clin Infect Dis 2013; 56: 1554–1561.PMC364186823446627 Sharma‐Kuinkel BK, Wu Y, Tabor DE et al Characterization of alpha‐toxin hla gene variants, alpha‐toxin expression levels, and levels of antibody to alpha‐toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremia. J Clin Microbiol 2015; 53: 227–236.PMC429092825392350 Wu Y, Liu X, Akhgar A et al Prevalence of IgG and neutralizing antibodies against Staphylococcus aureus alpha‐toxin in healthy human subjects and diverse patient populations. Infect Immun 2018; 86: e00671–17.PMC582094029263109 Bubeck Wardenburg J, Patel RJ, Schneewind O. Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect Immun 2007; 75: 1040–1044.PMC182852017101657 Foster TJ, Geoghegan JA, Ganesh VK et al Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus . Nat Rev Microbiol 2014; 12: 49–62.PMC570829624336184 Alonzo FI, Torres VJ. The bicomponent pore‐forming leucocidins of Staphylococcus aureus . Microbiol Mol Biol Rev 2014; 78: 199–230.PMC405425424847020 Diep BA, Phung Q, Date S et al Identifying potential therapeutic targets of methicillin‐resistant Staphylococcus aureus through in vivo proteomic analysis. J Infect Dis 2014; 209: 1533–1541.PMC399757424280367 Thomsen IP, Dumont AL, James DB et al Children with invasive Staphylococcus aureus disease exhibit a potently neutralizing antibody response to the cytotoxin LukAB. Infect Immun 2014; 82: 1234–1242.PMC395799224379282 Handke LD, Hawkins JC, Miller AA et al Regulation of Staphylococcus aureus MntC expression and its role in response to oxidative stress. PLoS One 2013; 8: e77874.PMC381027624205007 Jenkins A, Diep BA, Mai TT et al Differential expression and roles of Staphylococcus aureus virulence determinants during colonization and disease. MBio 2015; 6: e02272–02214.PMC433756925691592 Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus . Clin Microbiol Rev 2000; 13: 16–34.PMC8893110627489 O'Reilly M, Kreiswirth B, Foster TJ. Cryptic alpha‐toxin gene in toxic shock syndrome and septicaemia strains of Staphylococcus aureus . Mol Microbiol 1990; 4: 1947–1955.2082151 DeLeo FR, Kennedy AD, Chen L et al Molecular differentiation of historic phage‐type 80/81 and contemporary epidemic Staphylococcus aureus . Proc Natl Acad Sci USA 2011; 108: 18091–18096.PMC320769422025717 Nienaber JJ, Sharma Kuinkel BK, Clarke‐Pearson M et al Methicillin‐susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins. J Infect Dis 2011; 204: 704–713.PMC315610421844296 Tabor DE, Yu L, Mok H et al Staphylococcus aureus alpha‐toxin is conserved among diverse hospital respiratory isolates collected from a global surveillance study and is neutralized by monoclonal antibody MEDI4893. Antimicrob Agents Chemother 2016; 60: 5312–5321.PMC499782327324766 Bayer AS, Ramos MD, Menzies BE et al Hyperproduction of alpha‐toxin by Staphylococcus aureus results in paradoxically reduced virulence in experimental endocarditis: a host defense role for platelet microbicidal proteins. Infect Immun 1997; 65: 4652–4660.PMC1756679353046 Patti JM, Allen BL, McGavin MJ et al MSCRAMM‐mediated adherence of microorganisms to host tissues. Annu Rev Microbiol 1994; 48: 585–617.7826020 Foster TJ, Hook M. Surface protein adhesins of Staphylococcus aureus . Trends Microbiol 1998; 6: 484–488.10036727 Schneewind O, Fowler A, Faull KF. Structure of the cell wall anchor of surface proteins in Staphylococcus aureus . Science 1995; 268: 103–106.7701329 Dumont AL, Nygaard TK, Watkins RL et al Characterization of a new cytotoxin that contributes to Staphylococcus aureus pathogenesis. Mol Microbiol 2011; 79: 814–825.PMC331203121255120 DuMont AL, Yoong P, Surewaard BG et al Staphylococcus aureus elaborates leukocidin AB to mediate escape from within human neutrophils. Infect Immun 2013; 81: 1830–1841.PMC364802023509138 Janesch P, Rouha H, Weber S et al Selective sensitization of human neutrophils to LukGH‐mediated cytotoxicity by Staphylococcus aureus and IL‐8. J Infect 2017; 74: 473–483.28237625 Inouye M, Dashnow H, Raven LA et al SRST2: Rapid genomic surveillance for public health and hospital microbiology labs. Genome Med 2014; 6: 90.PMC423777825422674 Bankevich A, Nurk S, Antipov D et al SPAdes: a new genome assembly algorithm and its applications to single‐cell sequencing. J Comput Biol 2012; 19: 455–477.PMC334251922506599Gardner SN, Slezak T, Hall BG. kSNP3.0: SNP detection and phylogenetic analysis of genomes without genome alignment or reference genome. Bioinformatics 2015; 31: 2877–2878.25913206Letunic I, Bork P. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. Nucleic Acids Res 2016; 44: W242–W245.PMC498788327095192 Tkaczyk C, Hua L, Varkey R et al Identification of anti‐alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol 2012; 19: 377–385.PMC329462622237895 Hua L, Hilliard JJ, Shi Y et al Assessment of an anti‐alpha‐toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus‐induced pneumonia. Antimicrob Agents Chemother 2014; 58: 1108–1117.PMC391089924295977